CLOs on the Move

AVEO Pharmaceuticals

www.aveopharma.com

 
AVEO Pharmaceuticals, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. AVEO Pharmaceuticals, Inc. is based in Cambridge, MA. You can find more information on AVEO Pharmaceuticals, Inc. at www.aveopharma.com
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

American Red Cross - St. Paul Area

American Red Cross - St. Paul Area is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Timicoin

The most reliable, completely - decentralized, health information exchange is waiting for you.

MedRisk

MedRisk is the leading provider of managed physical medicine for the workers` compensation industry and related market sectors. Unified through a uniquely integrated, US-based support model, we pride ourselves in combining clinical expertise with highly personal service and responsiveness. This focus allows us to offer distinct value to each stakeholder in the workers` comp process – carriers and TPAs, employers, adjusters and case managers, physicians, network providers and the patients themselves. In short, we`re here for you; at MedRisk, you`re never just a number – you`re an individual who deserves a solution tailored to your exact needs. We`re here to help you reach your goals and improve your outcomes – whatever they may be.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.

Delphi Behavioral Health Group

Delphi Behavioral Health Group is a growing network of addiction treatment facilities that provide the full spectrum of care to those who are ready to start on the road to addiction recovery.